Dergiler / Journal of Experimental and Clinical Medicine / 2022 / Cilt: 39 - Sayı: 4

An evaluation of IGF-1 and IGFBP-3 levels in patients receiving growth hormone therapy and these parameters therapeutic efficacy

Sayfa
1230–1234
Yayın Tarihi
2022-10-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

All three parameters’ mean values were significantly higher after one year compared to baseline. Δ IGF-1 and Δ IGFBP-3 values investigated in the fırst year of treatment together with basal IGF-1 levels can be a useful diagnostic tool in showing growth response in children with GHD started on GH therapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels in healthy children reflect endogenous growth hormone (GH) levels, and their daily variations are very low.
📊
Temel Bulgular & Veri:This study investigated the relationship between growth response and serum IGF-1 and IGFBP-3 levels before and on the first year of treatment in children with GH deficiency (GHD) started on GH therapy.
💡
Sonuç & Katkı:All three parameters’ mean values were significantly higher after one year compared to baseline. Δ IGF-1 and Δ IGFBP-3 values investigated in the fırst year of treatment together with basal IGF-1 levels can be a useful diagnostic tool in showing growth response in children with GHD started on GH therapy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Growth hormone · Growth hormone therapy · Insulin-like growth factor-1

Abstract

Serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels in healthy children reflect endogenous growth hormone (GH) levels, and their daily variations are very low. This study investigated the relationship between growth response and serum IGF-1 and IGFBP-3 levels before and on the first year of treatment in children with GH deficiency (GHD) started on GH therapy. The records of 44 patients diagnosed with GHD, under follow-up at the Adıyaman Education and Research Hospital Pediatric Endocrinology Clinic, and receiving GH therapy for at least one year were examined retrospectively. Patients’ ages, pubertal development stages, peak GH-responses to GH stimulation tests and height standard deviation scores (SDS) measured before and at the first year of treatment, and IGF-1 and IGFBP-3 levels were recorded. Girls represented 27 (61.4%) of the cases in the study and boys 17 (3.6%), with ages ranging between 0.5 and 16.6 years (mean=11.5±3.3). Partial GHD was present in 33 patients (75%) and complete GHD in 11 (25%). Basal height SDS, IGF-1 and IGFBP-3 values were compared with those after one year of treatment. Patients with basal IGF-1 levels < -2 SDS exhibited significantly higher growth responses (p < .05). All three parameters’ mean values were significantly higher after one year compared to baseline. Δ IGF-1 and Δ IGFBP-3 values investigated in the fırst year of treatment together with basal IGF-1 levels can be a useful diagnostic tool in showing growth response in children with GHD started on GH therapy.

🔖

Bu Makaleye Atıf Yap

AŞIK, A., BOLU, S. (2022). An evaluation of IGF-1 and IGFBP-3 levels in patients receiving growth hormone therapy and these parameters therapeutic efficacy. Journal of Experimental and Clinical Medicine, Cilt: 39 - Sayı: 4, 1230–1234. https://ajindex.com/articles/886794

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101(1):96-100
  2. Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, Cappa M, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab. 1996;81:3323-3327 3. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Daughaday WH, Rotwein P. Endocr Rev. 1989;10:68–91 4. Juul A, Skakkebaek NE. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3. J Pediatr. 1997 Feb;130(2):197-204
  3. Lifshitz F. Growth and Growth disorders. Edby Liftshitz F. Pediatric Endocrinology (5th ed) New York: İnforma Health Care Inc. 2007, pp 1-40, pp 65-90, pp 113-145 6. Reiter EO and Rosenfeld RG. Normal and aberrant growth In: Wilson JD, Foster DW, Kronenberg HM and Larsen PR (eds). Williams Textbook of Endocrinology (9th ed). Philadelphia: W.B. Saunders Co 1998, pp 1427-1505
  4. Günöz H. Büyüme bozuklukları, Pediatrik Endokrinoloji. Editörler Günöz H, Öçal G, Yordam N, Kutoğlu S: Pediatrik Endokrinoloji ve Oksoloji yayınları 1, Ankara: Kalkan Matbacılık, 2003, ss 43-62, ss 66-131
  5. Cinaz P, Güran T, Bereket A. Boy kısalığı olan çocuğa yaklaşım. Güncel Çocuk Sağlığı Pediatrik Endokrinoloji Dergisi, 2008, 3: 2-9
  6. Bang P, Ahmed SF, Argente J, Backeljauw P, Bettendorf M, Bona G, et al. Identification and management of poor response to growth-promoting therapy in children with short stature. Clin Endocrinol (Oxf) 2012;77:169-181 10. Kim JH, Kim SJ, Lee J, Shin CH, Seo JY. Factors affecting IGF-I level and correlation with growth response during growth hormone treatment in LG Growth Study. PLoS One. 2021 Jul 19;16(7):e0252283
  7. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990-93
  8. Wilson TA, Rose SR, Cohen P, Rogol DA, Backeljauw P, Brown R et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003;1